Epitalon is a synthetic four-amino-acid peptide first made in 1999. Most pharmacological studies of it come from one research group in Russia, and most of the research FDA reviewed was in animals.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no approved product containing it in any of the countries it checked.1 Human data are limited to a few small reports. FDA found no studies of epitalon in people with insomnia, the use it evaluated, and no clinical data supporting its safety.1 FDA staff recommended against adding epitalon to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6
Epitalon at a glance
What it is
A synthetic peptide of four amino acids (Ala-Glu-Asp-Gly). FDA treats it as a different substance from epithalamin, a pineal-gland extract it was modeled on.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidence
A few small reports, including one 20-day randomized study that measured a melatonin breakdown product rather than sleep. FDA found no studies in people with insomnia.1
Evidence strength
Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned
What is epitalon?
Epitalon is a synthetic peptide made of four amino acids: alanine, glutamic acid, aspartic acid and glycine. It is also called epithalon or AEDG. It was designed from the amino-acid content of epithalamin, an extract of cattle pineal glands, but FDA treats the two as different substances.1
Epitalon appears to have been first synthesized in 1999. It received a U.S. orphan-drug designation for retinitis pigmentosa in 2010, and that designation was withdrawn in 2016.1
FDA found epitalon promoted online by wellness clinics as an anti-aging product, but could not identify any pharmacy that compounds it, and no outsourcing facility had reported compounding it.1
How is epitalon thought to work?
Because the pineal gland helps regulate the sleep-wake cycle, researchers have proposed that epitalon could affect daily body rhythms. In older female monkeys, one study reported higher evening melatonin and lower evening cortisol after treatment.1
How epitalon would change melatonin levels is unknown. A laboratory study found it did not directly increase melatonin release from rat pineal glands, and FDA found no animal studies that measured sleep itself.1
FDA’s briefing notes reports that epitalon can activate telomerase and lengthen telomeres. FDA says this raises a concern that long-term exposure could carry a cancer risk, and that the available mouse studies were too limited to rule that out.1
What do human studies show?
FDA evaluated epitalon for insomnia and found no studies of it in people with insomnia.1
The main human study FDA reviewed was a small 2021 randomized, placebo-controlled study in women working night shifts. Its authors reported that a melatonin breakdown product rose with epitalon, but the study did not measure sleep, did not state whether it was blinded, and was short.1
FDA found no clinical studies assessing epitalon’s safety and no pharmacokinetic data in people. Its searches of FDA’s adverse-event databases through December 2025 found no reports.1
FDA concluded that there is a lack of evidence that epitalon works for insomnia and no clinical data to support its safety in people.1
What the evidence base contains
Small, short, or incompletely reported human study A 2021 randomized, placebo-controlled study in 40 women working night shifts that measured a melatonin breakdown product over 20 days. FDA notes it did not state whether it was blinded, did not measure sleep, and did not report safety data.1
Small, short, or incompletely reported human study A 2002 report in people with retinitis pigmentosa, an inherited eye disease, and a meeting abstract stating that epitalon had no side effects in elderly people without giving study details.1
Animal or laboratory research Studies in monkeys, rats and mice reporting changes in melatonin and cortisol levels and fewer spontaneous tumors in female mice. FDA found no animal studies that measured sleep.1
No. FDA’s May 2026 evaluation states that epitalon, in either its free-base or acetate form, is not a component of any FDA-approved drug and that there is no United States Pharmacopeia monograph for it.1
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5
FDA staff evaluated both forms of epitalon for that list for insomnia and recommended against adding either. They cited poor chemical characterization, a possible risk of immune reactions, no clinical safety data, a lack of evidence of effectiveness, and existing FDA-approved insomnia treatments.1
FDA’s compounding safety-risk page, last updated April 22, 2026, lists epitalon among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3
HHS’s policy document states that epitalon was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6
FDA’s Pharmacy Compounding Advisory Committee discussed epitalon on July 24, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For epitalon, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6
HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates from FDA-registered facilities supply the quality test results FDA staff found missing, that historical use is now documented, and that FDA staff’s safety concerns are based on how epitalon might act rather than on observed harm. FDA staff had concluded that no clinical data support its safety in people.1,6
The policy does not make epitalon an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6
Timeline
Epitalon appears to have been first synthesized, according to the literature FDA reviewed.1
Epitalon receives a U.S. orphan-drug designation for retinitis pigmentosa. The designation was withdrawn on January 6, 2016.1
Epitalon is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
A Federal Register notice announces the July advisory-committee meeting that will discuss epitalon and opens a public comment docket.4
Epitalon leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
FDA staff date their evaluation recommending that epitalon not be added to the 503A bulks list.1
HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists epitalon among six peptide substances used in compounding.5,6
What is still unknown?
Whether epitalon improves sleep or any other health outcome in people: FDA found no studies in people with insomnia or other conditions that measured clinical outcomes.1
Its safety in people, including with long-term use, and whether its reported effect on telomeres carries a cancer risk.1
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1
Whether FDA’s rulemaking will add epitalon to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Epitalon: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Epitalon are the records PeptideScanner has selected and published, not every registration or paper about Epitalon. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked not available.
Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.↗↗
What the reviewed sources report
These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.↗↗
What remains unresolved?
Which translated or related reports describe the same participants?↗↗
Do controlled studies assess patient-important outcomes and adequately report adverse events?↗↗
Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.12
Bottom line from this bounded source set
These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.12
Reviewed study record
Retinal degeneration: mixed preclinical and clinical report
Design
The publication describes experiments in rats and clinical observations in patients with degenerative retinal lesions.1
Population
The abstract does not state the number of patients or their allocation to a comparator.1
Outcomes reported
The authors reported a positive clinical effect in 90% of cases and retinal effects in rats.1
Limitations
The clinical endpoint, comparator, follow-up and adverse events are insufficiently described in the abstract. The reported percentage is not a controlled effect estimate, and animal findings cannot establish human benefit.1
Reviewed study record
Circadian biomarkers
Design
The report examines AEDG and melatonin-related and clock-gene measurements in people with altered melatonin production.2
Population
The abstract does not give a sufficiently detailed enrollment and allocation account.2
Outcomes reported
The authors reported changes in urinary melatonin metabolite levels and clock-gene expression.2
Limitations
Biomarker changes do not establish better sleep, reduced disease or longer lifespan. Full-text and related-report reconciliation are required to assess design, participant overlap and harms.2
Melatonin measurements do not establish an insomnia benefit
FDA’s July 2026 briefing found no studies evaluating the nominated substances in patients with insomnia. Changes in melatonin or its metabolites were not accompanied by clinical outcomes establishing that proposed use. FDA PDF pp. 40 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Human exposure is different from an adequate safety study
The briefing describes a 20-person exposure report without safety data and an abstract making a safety claim without essential methods. FDA also notes that it could not evaluate one Russian-language full article in English. FDA PDF pp. 36, 37 ↗
No reported events is not proof of safety
FDA’s cited adverse-event searches retrieved no reports, but the briefing explains voluntary-reporting and information limits. It separately found insufficient clinical safety data, especially for the proposed subcutaneous route. FDA PDF pp. 36, 38 ↗
Preclinical findings leave unresolved questions
FDA considered the animal studies too limited in duration and design to characterize genotoxic or carcinogenic potential. Mechanistic concerns in the briefing are not proof that epitalon causes cancer in people. FDA PDF pp. 40 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.
140 retrieved · 2 included · 0 excluded · 138 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"epitalon"[Title/Abstract] OR "epithalon"[Title/Abstract] OR "AEDG"[Title/Abstract]
Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
Full-text appraisal, study-family linkage and citation follow-up remain open.
Showing 25 of 140 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 33280326 — include: Selected human report; abstract and record metadata reviewed. Study families: AEDG-2020-2021-circadian-reports-linkage-unresolved.
PubMed 12195242 — include: Selected human report; abstract and record metadata reviewed. Study families: epitalon-2002-retinal-report.
PubMed 42209466 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42021992 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41490200 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41240216 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41020860 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40908429 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40493162 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 40141333 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39788414 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39518916 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 38430634 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 39742404 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 36979488 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 37042594 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 35890947 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 35413689 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 35408963 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 34502859 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 34998008 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 33993656 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 32987757 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 31808038 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 31677028 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Epitalon?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
PubMed bibliography
Publication composition
1 of 24 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 1Review 1
Bibliography fields unavailable here for 23 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
26
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 26 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule.
PubMed lists PMID 42884164 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug epitalon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
Selected records span November 15, 2012 to October 20, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 42884164 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug epitalon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 40493162 at 2026-07-30T16:14:11.014Z. PubMed recorded a metadata revision date of 2026-06-13 and an Entrez history date of 2025-06-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41240216 at 2026-07-30T16:20:41.667Z. PubMed recorded a metadata revision date of 2026-05-20 and an Entrez history date of 2025-11-15. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 12209581 at 2026-07-30T16:30:44.156Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2002-09-05. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25535022 at 2026-07-30T20:43:08.960Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2014-12-24. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 14501183 at 2026-07-30T20:44:18.228Z. PubMed recorded a metadata revision date of 2019-11-08 and an Entrez history date of 2003-09-23. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 11087911 at 2026-07-30T20:48:24.194Z. PubMed recorded a metadata revision date of 2019-08-31 and an Entrez history date of 2000-11-23. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 12049808 at 2026-07-30T20:50:08.377Z. PubMed recorded a metadata revision date of 2019-07-20 and an Entrez history date of 2002-06-07. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 12101568 at 2026-07-30T21:22:56.967Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2002-07-10. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 15490730 at 2026-07-30T21:35:53.278Z. PubMed recorded a metadata revision date of 2016-10-21 and an Entrez history date of 2004-10-20. PeptideScanner associated this retained record with the identity slug epitalon. These dates describe PubMed metadata history, not the article's original publication date.↗